KALC 2025

Session VII (C).
Satellite Symposium III (A).		Room A (Grand Ballroom 3)
Date & Time	November 7(Fri), 08:20-09:00
Chair(s)	TBD
Speaker	TBD TBD

Session VII (C).
Session V (A). Novel immunotherapies beyond the PD1 pathway		Room A (Grand Ballroom 3)
Date & Time	November 7(Fri), 09:10-10:10
Chair(s)	Dong-Wan Kim (Seoul National Univ., Korea), Aron Lisberg (University of California, USA)
Speaker	09:10-09:25 Beyond PD-L1 axis inhibition: Where are we going? Aron Lisberg (University of California, USA) 09:25-09:40 Bispecifics and T cell engagers: Fighting against immune desert Jeongmin Seo (Seoul National Univ., Korea) 09:40-09:55 Combining ICIs with ADCs is the way to go? Sun Min Lim (Yonsei Univ., Korea) 09:55-10:10 Cellular therapies: Breaking the glass ceiling? Ben Creelan (H. Lee Moffitt Cancer Center & Research Institute, USA)

Session VII (C).
Session VI (A). Challenges during immunotherapy		Room A (Grand Ballroom 3)
Date & Time	November 7(Fri), 10:25-11:25
Chair(s)	Jae Cheol Lee (Univ. of Ulsan., Korea), Jordi Remon Masip (Institut Gustave Roussy, France)
Speaker	10:25-10:40 Should we exclude immunotherapy in case of advanced NSCLC with oncogenic addiction? Jordi Remon Masip (Institut Gustave Roussy, France) 10:40-10:55 When can or should anti-PD(L)-1 be stopped in advanced NSCLC? Jun Hyeok Lim (Inha Univ., Korea) 10:55-11:10 Is it feasible to restart immunotherapy after severe immune-related toxicity? Jinyong Kim (Sungkyunkwan Univ., Korea) 11:10-11:25 Immunotherapy and brain metastases Thomas John (Peter MacCallum Cancer Centre, Australia)

Session VII (C).
Luncheon Symposium II.		Room A+B+C (Grand Ballroom)
Date & Time	November 7(Fri), 11:40-12:20
Chair(s)	TBD
Speaker	11:40-12:20 TBD TBD

Session VII (C).
Plenary Session II.		Room A+B+C (Grand Ballroom)
Date & Time	November 7(Fri), 12:50-13:30
Chair(s)	Myung Ju Ahn (Sungkyunkwan Univ., Korea)
Speaker	12:50-13:30 Current uses and pitfalls of liquid biopsy in NSCLC Natasha B. Leighl (Princess Margaret Cancer Centre, Canada)

Session VII (C).
Session VII (A). Surgery in the chemoimmunotherapy era: Global perspectives		Room A (Grand Ballroom 3)
Date & Time	November 7(Fri), 13:50-14:50
Chair(s)	Suk Ki Cho (Seoul National Univ., Korea), Alessandro Brunelli (St. James's University Hospital, UK)
Speaker	13:50-14:05 Refining surgical boundaries after neoadjuvant therapy in lung cancer Samina Park (Seoul National Univ., Korea) 14:05-14:20 Optimal nodal management strategies after induction therapy: Scope, challenges, and surgical precision Mong-Wei Lin (National Taiwan University Hospital, Taiwan) 14:20-14:35 Managing pCR in lung cancer: the evolving role of ctDNA in postoperative strategy Jeonghwan Youk (Seoul National Univ., Korea) 14:35-14:50 Real-world surgical outcomes after neoadjuvant chemoimmunotherapy: The European experience Alessandro Brunelli (St. James's University Hospital, UK)

Session VII (C).
Session VIII (A). Stage-Specific considerations and dilemmas		Room A (Grand Ballroom 3)
Date & Time	November 7(Fri), 15:05-16:05
Chair(s)	Gong Yong Jin (Jeonbuk National Univ., Korea), Jong Ho Cho (Sungkyunkwan Univ., Korea)
Speaker	15:05-15:25 Imaging controversies in lung cancer staging Won Gi Jeong (Chonnam National Univ., Korea) 15:25-15:45 Systematic EBUS Staging to guide therapy June hong Ahn (Yeungnam Univ., Korea) 15:45-16:05 Should yp-staging be defined in future editions of the TNM classification system? Young Tae Kim (Seoul National Univ., Korea)

Session VII (C).
Session I (B). Insights into lung cancer pathology		Room B (Grand Ballroom 2)
Date & Time	November 7(Fri), 09:10-10:10
Chair(s)	Jin-Haeng Chung (Seoul National Univ., Korea), Mari Mino-Kenudson (Massachusetts General Hospital, USA)
Speaker	09:10-09:30 Intraoperative evaluations of surgical margins/STAS Mari Mino-Kenudson (Massachusetts General Hospital, USA) 09:30-09:50 Pitfalls in intraoperative evaluations: Benign versus malignant Dong Hoon Shin (Pusan National Univ., Korea) 09:50-10:10 Tissue is the issue: Maximizing molecular insights from small biopsy and cytology samples Yeoun Eun Sung (The Catholic Univ. of Korea, Korea)

Session VII (C).
Session VI (B). Unlocking lung cancer: Biological discoveries		Room B (Grand Ballroom 2)
Date & Time	November 7(Fri), 10:25-11:25
Chair(s)	Seung Yeon Ha (Gachon Univ., Korea), In-Jae Oh (Chonnam National Univ., Korea)
Speaker	10:25-10:40 Decoding systemic inflammation in lung cancer: Toward precision immuno-oncology Jae-Ho Cho (Chonnam National Univ., Korea) 10:40-10:55 Integrative proteogenomics identifies non-small cell lung cancer subtypes associated with chromosomal instability and enhanced kinase activity Joon-Yong An (Korea Univ., Korea) 10:55-11:10 Lepidic adenocarcinoma emerges from alveolar type 1 cells: Rethinking tumorigenesis and clinical implications Jung-Ki Yoon (Seoul National Univ., Korea) 11:10-11:25 Application of lung cancer organoids in precision medicine Jinwook Choi (GIST, Korea)

Session VII (C).
Session VII (B). Biology and novel agents in SCLC		Room B (Grand Ballroom 2)
Date & Time	November 7(Fri), 13:50-14:50
Chair(s)	Hye Ryun Kim (Yonsei Univ., Korea), TBD
Speaker	13:50-14:05 Recent developments in genomics and translational research of SCLC Esra Akbay (University of Texas Southwestern Medical Center, USA) 14:05-14:20 TBD TBD 14:20-14:35 Rethinking radiotherapy in the era of new standards for SCLC Young Seob Shin (Univ. of Ulsan, Korea) 14:35-14:50 New drugs in development for SCLC: In search of new hope Se Hyun Kim (Seoul National Univ., Korea)

Session VII (C).
Session VIII (B). Decoding the tumor microenvironment: A high-tech revolution		Room B (Grand Ballroom 2)
Date & Time	November 7(Fri), 15:05-16:05
Chair(s)	Byoung Chul Cho (Yonsei Univ., Korea), Woong-Yang Park (GxD Inc. & Sungkyunkwan Univ., Korea)
Speaker	15:05-15:20 Latest trend in Multiplex IHC technology for TME research Gil-Je Lee (Akoya biosciences, Inc, Korea) 15:20-15:35 Spatial transcriptomic landscape of NSCLC Yoon Kyung Jwon (Seoul National Univ., Korea) 15:35-15:50 Predicting the TME composition and therapeutic responses using multi-omic technology Woong-Yang Park (GxD Inc. & Sungkyunkwan Univ., Korea) 15:50-16:05 Translating TME research into precision oncology Jong-Eun Park (KAIST, Korea)

Session VII (C).
Closing Symposium (B).		Room B (Grand Ballroom 2)
Date & Time	November 7(Fri), 16:05-16:45
Chair(s)	TBD
Speaker	16:05-16:45 TBD TBD

Session VII (C).
Satellite Symposium III (C).		Room C (Grand Ballroom 1)
Date & Time	November 7(Fri), 08:20-09:00
Chair(s)	TBD
Speaker	TBD TBD

Session VII (C).
Session V (C). Oral Presentation II		Room C (Grand Ballroom 1)
Date & Time	November 7(Fri), 09:10-10:10
Chair(s)	TBD
Speaker	TBD TBD TBD TBD TBD TBD TBD TBD

Session VII (C).
Session VI (C). Oral Presentation III		Room C (Grand Ballroom 1)
Date & Time	November 7(Fri), 10:25-11:25
Chair(s)	TBD
Speaker	TBD TBD TBD TBD TBD TBD TBD TBD

Session VII (C).
Session VII (C). EGFR-Mutant NSCLC: Optimal regimen & rationale		Room C (Grand Ballroom 1)
Date & Time	November 7(Fri), 13:50-14:50
Chair(s)	Jeong-Seon Ryu (Inha Univ., Korea), Grace Dy (Rose Well Park Cancer Institute, USA)
Speaker	13:50-14:05 Mono or Combi, is Two really better than One? Derek De-Rui Huang (National Taiwan University, Taiwan) 14:05-14:20 What should we combine with TKI (Chemo Antibody or ADC) Grace Dy (Rose Well Park Cancer Institute, USA) 14:20-14:35 What is the best sequence for EGFR-Mutant NSCLC? Current options to future options Lyudmila A. Bazhenova (University of California San Diego, USA) 14:35-14:50 Any new treatment options under development in EGFR-Mutant NSCLC currently not approved? Byoung Chul Cho (Yonsei Univ., Korea)

Session VII (C).
Session VIII (C). Multi-omics and AI-driven precision in lung cancer		Room C (Grand Ballroom 1)
Date & Time	November 7(Fri), 15:05-16:05
Chair(s)	Ho Yun Lee (Sungkyunkwan Univ., Korea), Se Hoon Lee (Sungkyunkwan Univ., Korea)
Speaker	15:05-15:20 Multimodal and multi-omics biomedical AI for precision oncology: A comprehensive overview Chan-Young Ock (Lunit, Korea) 15:20-15:35 Multi-omics-based subtyping of NSCLC Hee Sang Hwang (Univ. of Ulsan, Korea) 15:35-15:50 Multi-omics analysis for discovering therapeutic targets in lung cancer Ken Asada (National Cancer Center Research Institute, Japan) 15:50-16:05 LLMs under the microscope: Using it right in medical research and practice Seong Ho Park (National Cancer Center Research Institute, Korea)

Session VII (C).
Joint Symposium with HIRA(Korean) (D). 가이드라인과 급여기준		Room D (Emerald)
Date & Time	November 7(Fri), 09:10-10:25
Chair(s)	이세훈 (성균관의대), 박인규 (서울의대)
Speaker	09:10-09:30 폐암 가이드라인에 나타난 새로운 치료법 이윤규 (성균관의대) 09:30-09:50 폐암 가이드라인에 나타난 새로운 진단법 김태정 (가톨릭의대) 09:50-10:10 최신 치료법이 건강보험에 반영되는 과정 및 가이드라인의 의미 김국희 (건강보험심사평가원) 10:10-10:25 패널토의: 발전적인 급여 등재 과정을 위한 학회와 심평원의 제언 및 논의 이윤규 (성균관의대), 김태정 (가톨릭의대), 김국희 (건강보험심사평가원)

Abstract No.	Presentation Time	Abstract Title	Presenter Name	Affiliation	Country
A-0186	14:45-14:55	Spatial transcriptomics reveals spatially diverse cancer-associated fibroblasts in lung squamous cell carcinoma linked to tumor progression	Kwon Joong Na	Seoul National University	Korea
A-0184	14:55-15:05	Single-cell RNA sequencing revealed that changes in monocytes are involved in the prognosis of durvalumab consolidation therapy following chemoradiotherapy	Duk Ki Kim	Chungnam National University	Korea
A-0105	15:05-15:15	Landscape of tumor heterogeneity and tumor mutational burden (TMB) in non-small cell lung cancer (NSCLC)	Jong Yeob Kim	Feinberg School of Medicine, Northwestern University	USA
A-0127	15:15-15:25	Induction of malignant transformation in human bronchial epithelial cells and lung organoids by chronic exposure to whole cigarette smoke extract	Joo-Eun Lee	Chungnam National University	Korea
A-0057	15:25-15:35	Identification of GREM-1 and GAS6 as specific biomarkers for cancer-associated fibroblasts derived from patients with non-small cell lung cancer	Bo-Guen Kim	Kangbuk Samsung Medical Center	Korea
A-0042	15:35-15:45	Spatially defined co-culture model of non-small cell lung cancer organoids and cancer-associated fibroblasts to investigate phenotypic heterogeneity	Cheol-Kyu Park	Chonnam National University	Korea

Abstract No.	Presentation Time	Abstract Title	Presenter Name	Affiliation	Country
A-0226	09:10-09:20	Perioperative outcomes of neoadjuvant chemoimmunotherapy followed by surgery in stage II-III NSCLC: A real-world study	Junghee Lee	Samsung Medical Center	Korea
A-0214	09:20-09:30	Preliminary analysis of lazertinib consolidation therapy in patients with locally advanced, unresectable, EGFR mutated NSCLC following chemoradiation therapy: PLATINUM trial	Sung Yong Lee	Korea University	Korea
A-0204	09:30-09:40	What Is the Optimal Dose and Fractionation Schedule for Inoperable Node-Negative Large (>5 cm) Non-Small Cell Lung Cancer?	Ye Jin Yoo	Asan Medical Center	Korea
A-0108	09:40-09:50	Double lung transplantation in patients with metastatic lung-limited non-small cell lung carcinoma (NSCLC): A case series	Young Chae	Northwestern University Feinberg School of Medicine	USA
A-0069	09:50-10:00	Normal brain-sparing radiotherapy versus whole brain radiotherapy for multiple brain metastasis from non-small cell lung cancer	Sangjoon Park	Severance Hospital	Korea
A-0046	10:00-10:10	Refining patient selection for prophylactic cranial irradiation in limited-stage small-cell lung cancer: Insights from a Korean multi-institutional cohort study	Hye In Lee	Asan Medical Center	Korea

Abstract No.	Presentation Time	Abstract Title	Presenter Name	Affiliation	Country
A-0080	10:25-10:35	Real-world insights: Treatment patterns and overall survival in patients with small-cell lung cancer in South Korea a single center experience	Sehhoon Park	Samsung Medical Center, Sungkyunkwan University School of Medicine	Korea
A-0196	10:35-10:45	AI-powered pathologic response evaluation of post-neoadjuvant chemoimmunotherapy in NSCLC patients	Kwon Joong Na	Seoul National University	Korea
A-0167	10:45-10:55	Enhanced thrombopoiesis supplies PD-L1 to circulating immune cells via the generation of PD-L1-Expressing platelets in lung cancer patients	Jae Ho Cho	Chonnam National University Medical School	Korea
A-0230	10:55-11:05	Chemotherapy plus immune checkpoint inhibitors in non-small cell lung cancer with actionable gene alterations other than EGFR, ALK, and ROS1	Ji Eun Shin	The Catholic University of Korea St. Vincent's Hospital	Korea
A-0131	11:05-11:15	Sequential hypofractionated radiotherapy followed by anti-PD-L1 atezolizumab for recurrent or refractory small cell lung cancer	Yang-Gun Suh	National Cancer Center	Korea
A-0035	11:15-11:25	Imaging trajectory of transformation into small-cell carcinomas from lung adenocarcinomas undergoing TKI treatment: radiomic prediction	Jihwan Choi	Samsung Medical Center	Korea

Abstract No.	Poster No.	Abstract Title	Presenter Name	Affiliation	Country
A-0215	PE1-01	Engineering precision medicine for lung cancer: Antibody-mimetic scaffolds targeting EGFR	Tushar Kushwaha	All Institute of Medical Sciences	India
A-0128	PE1-02	TP53 mutations in Belarusian patients with non-small cell lung cancer	Hanna Shchayuk	Institute of Genetics and Cytology, National Academy of Sciences of Belarus	Belarus
A-0109	PE1-03	Optimized exosomal miRNA panels for early detection of non-small cell lung cancer	Da Hyun Kang	Chungnam National University	Korea
A-0060	PE1-04	Anticancer effect of Columbianadin against benzopyreneinduced lung cancer in rats: Role of PI3K/Akt/FoxO1 and inflammatory pathway	Vikas Kumar	Sam Higginbottom University of Agriculture, Technology & Sciences	India
A-0047	PE1-05	Role of exosomal proteins in brain-specific metastasis of lung cancer	Dong Ha Kim	Asan Medical Center	Korea
A-0238	PE1-06	The influence of knowledge and attitudes on smoking decisions: Case study of the Pandeyan Boyolai village community, Central Java.	Rinita Istiqomah	Yogyakarta State University	Indonesia
A-0237	PE1-07	Driver genes expression and fusions in patients with lung cancer	Yuliya Stankevich	Institute of Genetics and Cytology of the National Academy of Sciences of Belarus	Belarus
A-0233	PE1-08	Association between long non-coding RNA HOTAIR polymorphism and lung cancer risk: A meta-analysis	Farhana Sultana Mitu	Islamic University	Bangladesh
A-0232	PE1-09	A meta-analytic approach to find the association between polymorphism with in MicroRNAs and lung cancer risk	Md Abdullah Al Maruf	Islamic University	Bangladesh
A-0228	PE1-10	CTSC regulates cell growth in small cell lung cancer via YAP/PAR2 signaling pathway	Nayoung Kim	Chungnam National University Hospital	Korea
A-0208	PE1-11	Lung Organoid to understand mechanism of therapeutic resistance in lung cancer	Jinwook Choi	School of Life Sciences, Gwangju Institute of Science and Technology (gist)	Korea
A-0185	PE1-13	The impact of Living-Donor Lobar Lung Transplantation (LDLLT) procedure on the sexual function of donors and recipients: A systematic review	Rosinta Hotmaida P Purba	The Pranala Institute	Indonesia
A-0179	PE1-14	Loss of Cereblon (CRBN) enhances lung cancer cell migration and invasion through regulation of cystathionine -synthase (CBS)	Kihun Kim	Gwangju Institute of Science and Technology	Korea
A-0173	PE1-15	Parallel Accumulation-Serial Fragmentation for in-depth proteomic analysis of bronchoalveolar lavage fluid of non-small cell lung cancer	Seung Hyeun Lee	Kyung Hee University Medical Center	Korea
A-0164	PE1-16	Butanolic fraction of Asparagus racemosus root alters the JAK/STAT3 Signaling Pathway to mitigate metastasis, apoptosis, and proliferation in lung cancer	Niti Singh	Marlabs Innovation Pvt Ltd.	India
A-0161	PE1-17	Utilizing machine learning methodologies to forecast the occurence of lung cancer in patients of central region.	Manvendra Singh	Hmfa Miet	India
A-0160	PE1-18	Solid Lipid Nanoparticle of Ganodric acid in the treatment against benzopyreneinduced lung cancer in rats: Nrf2/HO-1 signaling pathway	V Kumar	Shalom Institute of Health & Allied Sciences	India
A-0156	PE1-19	Solid lipid nanoparticles of gallic acid enhances apoptosis and proliferation in rats to lessen lung cancer induced by diethylnitrosamine/2-acetylaminofluorene.	Deepika Singh	Shuats	India
A-0154	PE1-20	The incidence of hematologic paraneoplastic syndromes in newly diagnosed lung cancer patients	Roland Helmizar	Baiturrahmah University	Indonesia
A-0114	PE1-22	A pilot study to discover potential early NSCLC biomarkers in the Filipino secretome	Josemaria Alejandro Corpuz	University of the Philippines-Diliman	Philippines
A-0090	PE1-23	Recapitulation tumor microenvionments with lung cancer organoids for drug screening study	Insu Lee	Seoul National University Bundang Hospital	Korea
A-0088	PE1-24	What is our role to reduce lung cancer mortality rates?: Case studies of 7 countries with the highest lung cancer	Nadia Fazira	Andalas University	Indonesia
A-0087	PE1-25	ARAF p.S214C Mutation Enhances Sorafenib Response in Lung Cancer	Carol Lee	The Chinese University of Hong Kong	Hong Kong
A-0076	PE1-27	Enhancing tumoroid applications with regenix in advanced 3D cell culture models	Da Hye Song	Cellartgen	Korea
A-0068	PE1-28	Regenix in lung cancer PDX models: Advancing research and therapeutic potential	Da Hye Song	Cellartgen	Korea
A-0063	PE1-29	Synergistic anticancer effects of Niclosamide and Osimertinib: Repurposing drugs in autophagy for the treatment of EGFR-mutant lung cancer cells	Yuan-Ming Tsai	Tri-Service General Hospital, National Defense Medical Center	Taiwan
A-0051	PE1-30	Identification of Guanine-quadruplex forming DNA aptamer: A promising therapeutic strategy for EGFR overexpressed non-small cell lung cancer	Deepa Singh	All Institute of Medical Sciences	India
A-0050	PE1-31	Austrian biobanking and biomolecular resources research infrastructure - Important partner for research on biological samples	Luka Brcic	Medical University of Graz	Austria
A-0049	PE1-32	Clinical and genomic features of different KRAS Subtypes in non-small cell lung cancer	Soo Han Kim	Pusan National University Hospital	Korea

Abstract No.	Poster No.	Abstract Title	Presenter Name	Affiliation	Country
A-0151	PE1-34	Network pharmacology study revealed the multitargets anticancer mechanism of sesamin in NSCLC	Reny Rosalina	University of Palangka Raya	Indonesia
A-0250	PE1-35	Utilizing machine learning algorithms for enhanced lung cancer diagnosis through imaging biomarkers	Divo Helmizar	Stan Jakarta	Indonesia
A-0239	PE1-36	Deep-learning model for personalized recurrence prediction in early-stage non-small cell lung cancer	Daehwan Lee	Spidercore Inc.	Korea
A-0093	PE1-38	Increased risk of lung cancer in individuals with nontuberculous mycobacterial pulmonary disease: A Korean population-based study	Dongwon Park	Hanyang University Medical Center	Korea
A-0086	PE1-39	Deep-learning-driven prediction of lung cancer recurrence using integrated immune profiling and radiomic features from computed tomography scans	Rifaldy Fajar	Yogyakarta State University	Indonesia

Others
Abstract No.	Poster No.	Abstract Title	Presenter Name	Affiliation	Country
A-0064	PE1-40	Harnessing computer-aided drug discovery for the development of potent allosteric inhibitors targeting EGFR in NSCLC	Mdaliasif Noor	Chonbuk National University Hospital	Korea
A-0120	PE1-42	The association between prevalence of tobacco use, nitrous oxide emissions and current health expenditure toward lung cancer in asian countries	Devi Yulia Rahmi	Universitas Andalas	Indonesia
A-0139	PE1-43	Self efficacy and quality of life in lung cancer patients: Systematic reviews	Mega Dwi Septivani	Padang State Polytechnic	Indonesia
A-0166	PE1-44	Revealed intermittent fasting benefit: How does the systematic review suggest lung cancer patients should undergo the most effective fasting?	Yesika Simbolon	Atmajaya University	Indonesia

Mesothelioma / Thymic & Other Thoracic Malignancies
Abstract No.	Poster No.	Abstract Title	Presenter Name	Affiliation	Country
A-0126	PE2-07	Pediatric mesothelioma: a case report	Heae Surng Park	Ewha Womans University Medical Center	Korea
A-0125	PE2-08	The impact of prevalence of annual freshwater withdrawals, drinking water services and air pollution toward mesothelioma cancer	Ferza Alfath	Alumnus Universitas Andalas	Indonesia
A-0118	PE2-09	Characterization of tumor-infiltrating B cells in malignant pleural mesothelioma and thymic carcinoma using single-cell RNA sequencing and deep learning	Sahnaz Vivinda Putri	International University Semen	Indonesia
A-0020	PE2-10	Well differentiated papillary mesothelial tumor from retrospective diagnosis for 10 years (2013 - 2023)	Nguyen Son Lam	Pham Ngoc Thach Hospital	Vietnam

Palliative Care
Abstract No.	Poster No.	Abstract Title	Presenter Name	Affiliation	Country
A-0115	PE3-14	Digital aging and mental health deteriorationsof among Indonesian elderly with lung cancer: A psychosocioeconomic analysis	Lintong Hottua Simbolon	The Pranala Institute	Indonesia
A-0256	PE3-15	The significance of music-based interventions in lung cancer patients in palliative care : A bibliometric analysis	Mery Enjelica Cristin	Universitas Palangka Raya	Indonesia
A-0249	PE3-16	Music therapy and spiritual nursing care for lung cancer sufferers in Indonesia post surgery	Yusril Yusril	Uin Sjech M. Djamil Djambek Bukittinggi	Indonesia
A-0241	PE3-17	Palliative care for lung cancer patients: Before and during the COVID-19 pandemic	Yusril Yusril	Uin Sjech M. Djamil Djambek Bukittinggi	Indonesia
A-0213	PE3-18	Quality of life among chronic lung disease patients in Indonesia: Insights from the Indonesia family life survey	Derizal Derizal	Ip Trisakti	Indonesia
A-0207	PE3-19	Analysis of health management of mesothelioma patients in Indonesia, including early diagnosis, treatment, and palliative support.	Andi Makkasau Andi Ureng	Alami Gsb	Indonesia
A-0198	PE3-20	Best nudge to influence people's behaviour for better off: Choices architecture on lung cancer prevention?	Helen Try Juniasti	Cendrawasih University	Indonesia
A-0165	PE3-21	Prevention and treatment of lung disease disease: How community-based health care take the important role among 17k islands in Indonesia	Hepri Ardianson Purba	The Pranala Institute	Indonesia

Scientific Program